Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 7/20 | 0.44 |
| ▸ | MME | P08473 | 6/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31181198 | 0.85 | ALDH1A1 (0.47) | ALDH1A1MAPTPTGS1ACEMME | |
| SCHEMBL30658172 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MAPTPTGS1MMEDPP4 | |
| SCHEMBL29376144 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL30861836 | 0.77 | MAPT (0.52) | ALDH1A1MAPTPTGS1ACEMME | |
| SCHEMBL29527816 | 0.77 | ACE (0.56) | ALDH1A1MAPTPTGS1ACEMME | |
| SCHEMBL9698824 | 0.74 | DPP4 (0.52) | ACEMMECPA1ACE2DPP4 | |
| SCHEMBL380600 | 0.74 | DPP4 (0.52) | ACEMMECPA1ACE2DPP4 | |
| SCHEMBL159552 | 0.74 | DPP4 (0.52) | ACEMMECPA1ACE2DPP4 | |
| SCHEMBL380599 | 0.74 | DPP4 (0.52) | ACEMMECPA1ACE2DPP4 | |
| SCHEMBL476353 | 0.74 | DPP4 (0.52) | ACEMMECPA1ACE2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | AARS1, NSUN3, RNGTT | ALDH1A1 4757/4885MAPT 4068/4885PTGS1 3409/4885 |
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | AARS1, NSUN3, RNGTT | ALDH1A1 4757/4885MAPT 4068/4885PTGS1 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.